The Emerging Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Obesity, Mental Health and Addictive Disorders-View Presentation

Video Transcription

Video Summary

The session titled "The Emerging Role of Glucagon-like Peptide (GLP-1) Receptor Agonists in Obesity, Mental Health, and Addictive Disorders," moderated by Vikas Gupta, explored the expanding applications of GLP-1 receptor agonists. As noted in the session, GLP-1 agonists such as semaglutide, liraglutide, and terzepatide are primarily used to manage obesity and diabetes but are finding increased interest in treating mental health and addictive disorders due to their influence on neuropsychiatric hormones and inflammation. Dr. Holly Lofton detailed how these medications mimic native GLP-1, influencing appetite and promoting satiety, thus aiding in weight loss. Safety data indicated a minor incidence of psychiatric side effects but highlighted the importance of monitoring due to potential risks such as depression. Dr. Alpana Shukla shared insights from long-term studies, noting that patients with psychiatric comorbidities showed positive weight management results when using these drugs, stressing interdisciplinary cooperation in treatment planning. Dr. Jose Aleman discussed the metabolic challenges seen with atypical antipsychotics, indicating that GLP-1 receptor agonists could counteract these effects. Lastly, Dr. Lorenzo Leggio highlighted burgeoning research into GLP-1 applications for alcohol use disorder, citing strong preclinical evidence and some initial human data, advocating for more comprehensive human trials to confirm efficacy and safety. The session underscored the potential multidisciplinary roles GLP-1 receptor agonists could play beyond their current applications.

Keywords

GLP-1 receptor agonists

obesity management

mental health

addictive disorders

semaglutide

liraglutide

terzepatide

neuropsychiatric hormones

psychiatric side effects

interdisciplinary treatment

atypical antipsychotics

alcohol use disorder